Invention Grant
- Patent Title: Compounds and methods for reducing LRRK2 expression
-
Application No.: US16972822Application Date: 2019-06-27
-
Publication No.: US11332746B1Publication Date: 2022-05-17
- Inventor: Susan M. Freier
- Applicant: Ionis Pharmaceuticals, Inc.
- Applicant Address: US CA Carlsbad
- Assignee: Ionis Pharmaceuticals, Inc.
- Current Assignee: Ionis Pharmaceuticals, Inc.
- Current Assignee Address: US CA Carlsbad
- Agency: McNeill Baur PLLC
- International Application: PCT/US2019/039558 WO 20190627
- International Announcement: WO2020/006267 WO 20200102
- Main IPC: C12N15/11
- IPC: C12N15/11 ; C12N15/113 ; A61K47/02 ; A61K47/46 ; A61K31/7125 ; A61P25/16
Abstract:
Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of LRRK2 RNA in a cell or animal, and in certain instances reducing the amount of LRRK2 protein in a cell or animal Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least 5 one symptom or hallmark of a neurodegenerative disease. Such symptoms and hallmarks include ataxia, neuropathy, and aggregate formation. Such neurodegenerative diseases include Parkinson's disease.
Information query
IPC分类:
